No MAM: ALS Protein Breaks Mitochondria-Endoplasmic Reticulum Bond

The amyotrophic lateral sclerosis protein TDP-43 may exert its toxic effect by uncoupling mitochondria and endoplasmic reticulum, according to a paper in the June 3 Nature Communications. Where these two organelles meet, they form structures called mitochondria-associated ER membranes, aka MAMs, and TDP-43 can disrupt that interaction, report scientists from King’s College London. Senior author Christopher Miller and colleagues discovered this as they were following up on earlier results that another ALS protein, vesicle-associated membrane protein-associated protein-B (VAPB), reaches out from the ER to grab mitochondria. The authors posit that MAM alterations could explain many cellular ALS changes, including calcium dyshomeostasis and mitochondrial maladies.

When ER and mitochondrial membranes come close together, they build transient bridges—the MAMs. Researchers know little about this association, but MAMs have at least two major functions, said Eric Schon of Columbia University Medical Center in New York, who has linked MAMs to Alzheimer’s disease. For one, they manage calcium levels as the ions travel from the ER to the mitochondria. For another, they host synthesis of both cholesterol and phospholipids. Miller’s group previously reported that VAPB in the ER shakes hands with a mitochondrial protein that goes by the moniker protein tyrosine phosphatase-interacting protein 51 (PTPIP51) (De Vos et al., 2012).

Mutations in VAPB cause ALS, and the authors showed in their earlier paper that one such variant binds more tightly to PTPIP51 than wild-type. Like VAPB, TDP-43 contributes to ALS, and it renders mitochondria structurally abnormal and interferes with ER signaling pathways (see Aug 2010 news story; Shan et al., 2010). Might TDP-43 act via MAMs, as well?

To find out, co-first authors Radu Stoica and Kurt De Vos, who has moved to Alzheimer’s Research UK in Cambridge, expressed wild-type and mutant TDP-43 in mouse motor neuron NSC-34 cultures. Normally, about 12 percent of outer mitochondrial membranes butt up against the ER in MAMs. Both wild-type and mutant TDP-43 reduced this fraction by a third or more. The same occurred in a mouse model expressing wild-type human TDP-43; the percentage of mitochondrial membranes in the abutting MAMs was about half that in non-transgenic littermates.

Using co-immunoprecipitation, the authors showed that TDP-43 expression reduced binding of VAPB to PTPIP51 in the NSC-34 cells and spinal cords of the model mice. However, TDP-43 itself did not co-immunoprecipitate with VAPB or PTPIP51. The authors concluded that TDP-43 must control their interaction remotely. Researchers recently reported that TDP-43 activates glycogen synthase kinase-3β (GSK-3β; Ambegoakar and Jackson, 2011), and the Miller group hypothesized that this enzyme could be part of the link. Treating the cells with GSK-3β inhibitors boosted the amount of co-immunoprecipitated PTPIP51 and VAPB, whereas overexpressing GSK-3β diminished this measure. “Thus, TDP-43 activates GSK-3β and GSK-3β regulates the VAPB-PTPIP51 interaction,” the authors wrote. They claim that pathogenic TDP-43 may damage the MAMs, though the steps from TDP-43 to GSK-3β to MAM disruption are not yet understood. The study authors were unavailable to comment for this news article. Other researchers have found that inhibiting GSK-3 protects mouse neurons from the negative effects of the ALS gene superoxide dismutase 1 (see Apr 2013 news story).

Exactly how TDP-43 influences ALS, AD, and frontotemporal dementia is a research hotbed. The protein has been spotted co-localizing with the organelle (see Aug 2010 news story; Wang et al., 2013). “However, if TDP-43 regulates the association of mitochondria and ER via activation of GSK-3β, [then] TDP-43 would not necessarily need to be physically associated with these organelles to regulate this pathway,” Brian Freibaum of St. Jude Children’s Research Hospital in Memphis, Tennessee, wrote in an email to Alzforum.

The Calcium Connection
Because MAMs regulate calcium homeostasis, De Vos and Stoica hypothesized that TDP-43 might alter calcium levels in mitochondria and the cytosol. They used a drug to trigger calcium release from the ER in human embryonic kidney HEK293 cells, and tested if a TDP-43 transgene influenced that response. Cultures expressing TDP-43 contained slightly more cytosolic and less mitochondrial calcium than control cells. In fact, Miller and colleagues suggest that disrupting MAMs could lead to a number of problems seen in ALS neurons, including altered calcium homeostasis as well as mitochondrial damage, decreased ATP synthesis, and inappropriate activation of the unfolded protein response in the ER.

“It is unclear at this time how significantly this pathway may contribute to disease pathogenesis, but I think it is definitely worthy of future exploration,” Freibaum wrote. “I would be curious to see if there is evidence of decreased mitochondria-ER association in patient cells.”

ALS might not be the only neurodegenerative condition where MAMs go awry. In the case of Alzheimer’s, Schon’s group reported that presenilin 1 and 2 are found in MAMs, and γ-secretase acts there as well (Area-Gomez et al., 2009). In addition, they discovered that a MAM function—cholesteryl ester and phospholipid synthesis—is overactive in fibroblasts from people with Alzheimer’s (Area-Gomez et al., 2012). “We think that ER and mitochondria communication lies at the heart of AD,” said Schon (reviewed in Schon and Area-Gomez et al., 2012), though few other scientists share this view. Signs point to MAMs in Parkinson’s, too, with recent data that α-synuclein localizes to these points of organelle contact (Guardia-Laguarta et al., 2014). And there are hints MAMs may be involved in frontotemporal dementia, spinal muscular atrophy (see Sep 2010 news story), and Charcot-Marie-Tooth disease (Zuechner et al., 2004), Schon said. “I think that MAM is unexplored territory, and its importance is vastly underestimated.”

Primary Reference:
Stoica R, De Vos KJ, Paillusson S, Mueller S, Sancho RM, Lau KF, Vizcay-Barrena G, Lin WL, Xu YF, Lewis J, Dickson DW, Petrucelli L, Mitchell JC, Shaw CE, Miller CC. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat Commun. 2014 Jun 3;5:3996. [PubMed].

To view commentaries, primary articles and linked stories, go to the original posting on here.

Copyright © 1996–2015 Biomedical Research Forum, LLC. All Rights Reserved.

disease-als topic-preclinical
Share this: